Traditionally a small molecule drug raw ingredient and excipient supplier, Roquette has upped its position in the biopharmaceutical space and now offers dextrose for cell energy in the upstream process, and protein stabilisers in the downstream.
“We recognise the importance of biopharmaceuticals for diseases that were once thought impossible to treat or cure,” Roquette global market manager, BioPharma Carol Smith told Biopharma-Reporter.com.
“Just as the market is evolving, we are prepared to partner and collaborate with customers to advance the future of medicine.”
While the firm has supplied the biopharma industry for a number of years through repackages,
Roquette’s move into biologics has been helped by its knowledge about carbohydrates and their effect on cell growth, she continued, adding the firm is making “meaningful investments” to serve the Biopharma market
“We have been preparing for this by investing in new packaging, higher documentation, and additional testing requirements,” she said.
“Biopharma customers need to have access to technical information to make informed decisions to manage risk; we have prepared several technical packages to make it easier for them.”
The firm has three products available to clients – Lycadex glucose, Pearlitol mannitol and Neosorb sorbitol – but intends to increase its portfolio.
“We will continue to build the portfolio with additional products and services and ensure that our capabilities are aligned with our customer’s growth,” said Smith.